Signal Transduct Target Ther September 2024 PMID 39289339

Glucagon-like peptide-1 receptor: mechanisms and advances in therapy.

Zhikai Zheng, Yao Zong, Yiyang Ma, Yucheng Tian, Yidan Pang, Changqing Zhang, Junjie Gao

Download social card

Mentions

40
Peak: 1 in Sep 2024
across 5 sources since Sep 2024

Extended reach

1,298
potential audience

Total likes

45

Video views

596

Mentions per month

Sep 2024 – Dec 2025

Where it's discussed

  • News28 articles
  • Blogs4 articles
  • X / Twitter3 posts
  • Facebook3 posts
  • YouTube2 videos

AI synopsis

What people are saying

Several comments express a general acknowledgment of the article’s importance, such as noting that GLP-1 drugs have been available for a long time, indicating familiarity and recognition. The tone further reveals interest by discussing side effects like nausea and pancreatitis, which shows participants are engaged with practical concerns, though the impact is seen as moderate since the discussion mainly reinforces known information rather than urging immediate or widespread changes.

AgreementModerate agreement

Most discussions recognize the significance of the article, either acknowledging its thorough review or supporting its findings.

InterestModerate interest

Participants show moderate curiosity, mentioning the longstanding use of GLP-1 drugs and their effects.

EngagementModerate engagement

The conversations include references to side effects and drug efficacy, indicating a moderate level of detailed engagement.

ImpactNeutral impact

The overall tone suggests that while the article is respected, it doesn’t seem to be viewed as dramatically transformative but rather as an important reinforcement of existing knowledge.

Abstract in brief

  • The GLP-1 receptor (GLP-1R) is an important G protein-coupled receptor that interacts with the hormone GLP-1, which regulates blood sugar and lipid metabolism.
  • Recent innovations in GLP-1 medications have highlighted their effectiveness and expanding applications in treating various health issues.
  • The article reviews the development of GLP-1 drugs, their pharmacological properties, and their potential use in conditions like obesity, heart disease, and neurodegenerative diseases, emphasizing their therapeutic benefits.

Top posts

Most liked on X and Bluesky
Colleen Kupka
@CKupka10023 · X

@Gabepluguez There is a paper out there called "Glucagon-like peptide-1 receptor: mechanisms and advances in therapy. Great paper, these drugs have been out a very long time. Yes, side effects can occur, nausea, vomiting, and pancreatitis. However there are many that do just fine on it.

Dec 2, 2024 · 7 likes · 7 followers View post →
Mimi in Aus
@MimiinAus23 · X

Glucagon-like peptide-1 receptor: mechanisms and advances in therapy https://t.co/4FMr0qTpIM

Sep 18, 2024 · 2 likes · 48 followers View post →

All mentions

Omar Al Mukhtar, M.D.
@OGAlMukhtar · X

@MariaJonsson1 @Dominanski Glucagon-like peptide-1 receptor: mechanisms and advances in therapy | Signal Transduction and Targeted Therapy

Sep 9, 2025 · 1 like · 648 followers View post →
Colleen Kupka
@CKupka10023 · X

@Gabepluguez There is a paper out there called "Glucagon-like peptide-1 receptor: mechanisms and advances in therapy. Great paper, these drugs have been out a very long time. Yes, side effects can occur, nausea, vomiting, and pancreatitis. However there are many that do just fine on it.

Dec 2, 2024 · 7 likes · 7 followers View post →
Mimi in Aus
@MimiinAus23 · X

Glucagon-like peptide-1 receptor: mechanisms and advances in therapy https://t.co/4FMr0qTpIM

Sep 18, 2024 · 2 likes · 48 followers View post →